SKYE BIOSCIENCE DL -,001 Aktie

SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced the debut of its “Anatomy of Progress” nimacimab development update video series and availability of presentations related to the development of its anti-obesity drug, nimacimab, presented in multiple forums at the American Diabetes Association's (ADA) 85th Scientific Sessions held June 20-23, 2025, in Chicago, Illinois. The presentations are accessible at the following link.» Mehr auf globenewswire.com

SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it was selected to present new nimacimab data in its expanded preclinical model at the upcoming American Diabetes Association's (ADA) 85th Scientific Sessions. Skye will present in multiple forums at the ADA conference, which is being held June 20th – 23rd, 2025, at the McCormick Place Convention Center in Chicago, Illinois.» Mehr auf globenewswire.com

Squarepoint Ops LLC bought a new stake in shares of Skye Bioscience, Inc. (NASDAQ:SKYE – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 13,546 shares of the company’s stock, valued at approximately $38,000. Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Virtu Financial LLC purchased a new stake in Skye Bioscience during the fourth quarter valued at approximately $29,000. Wells Fargo & Company MN increased its holdings in Skye Bioscience by 49.0% during the fourth quarter. Wells Fargo & Company MN now owns 11,199 shares of the company’s stock valued at $32,000 after buying an additional 3,684 shares during the last quarter. Two Sigma Advisers LP purchased a new stake in Skye Bioscience during the fourth quarter valued at approximately $32,000. Jane Street Group LLC increased its holdings in Skye Bioscience by 195.5% during the fourth quarter. Jane Street Group LLC now owns 36,057 shares of the company’s stock valued at $102,000 after buying an additional 23,857 shares during the last quarter. Finally, Bank of America Corp DE increased its holdings in Skye Bioscience by 37.4% during the fourth quarter. Bank of America Corp DE now owns 39,257 shares of the company’s stock valued at $111,000 after buying an additional 10,696 shares during the last quarter. 21.09% of the stock is owned by hedge funds and other institutional investors. Skye Bioscience Price Performance SKYE opened at $2.37 on Wednesday. The firm has a market cap of $73.41 million, a P/E ratio of -2.89 and a beta of 1.69. Skye Bioscience, Inc. has a 1-year low of $1.14 and a 1-year high of $11.16. The company has a 50 day simple moving average of $2.07 and a two-hundred day simple moving average of $1.96. Skye Bioscience (NASDAQ:SKYE – Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.03. Equities analysts anticipate that Skye Bioscience, Inc. will post -1.04 earnings per share for the current year. Wall Street Analysts Forecast Growth A number of equities analysts have weighed in on SKYE shares. William Blair reiterated an “outperform” rating on shares of Skye Bioscience in a research report on Tuesday, May 20th. Craig Hallum dropped their price target on shares of Skye Bioscience from $18.00 to $14.00 and set a “buy” rating for the company in a research report on Friday, March 21st. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $16.60. Check Out Our Latest Stock Analysis on SKYE Skye Bioscience Company Profile (Free Report) Skye Bioscience, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.» Mehr auf defenseworld.net